Plasmatic miR-210, miR-221 and miR-1233 profile: potential liquid biopsies candidates for renal cell carcinoma
Metrics: PDF 1977 views | HTML 2471 views | ?
Francisca Dias1,2,3, Ana Luísa Teixeira1,2, Marta Ferreira4, Bárbara Adem1,5, Nuno Bastos1,5, Joana Vieira6, Mara Fernandes1,2,5, Maria Inês Sequeira4, Joaquina Maurício4, Francisco Lobo7, António Morais7, Jorge Oliveira7, Klaas Kok8 and Rui Medeiros1,2,5,9
1Molecular Oncology and Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal
2Research Department, LPCC- Portuguese League Against Cancer (NRNorte), Porto, Portugal
3ICBAS, Abel Salazar Institute for the Biomedical Sciences, University of Porto, Porto, Portugal
4Medical Oncology Department of the Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal
5FMUP, Faculty of Medicine, University of Porto, Porto, Portugal
6Genetics Department of the Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal
7Urology Department of the Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal
8Department of Genetics, University Medical Center, Groningen, The Netherlands
9CEBIMED, Faculty of Health Sciences, Fernando Pessoa University, Porto, Portugal
Ana Luísa Teixeira, email: [email protected]
Rui Medeiros, email: [email protected]
Keywords: circulating miRNAs, renal cell carcinoma, prognostic biomarkers
Received: January 12, 2017 Accepted: September 25, 2017 Published: October 11, 2017
Renal cell carcinoma (RCC) represents a challenge for clinicians since the nonexistence of screening and monitoring tests contributes to the fact that one-third of patients are diagnosed with metastatic disease and 20–40% of the remaining patients will also develop metastasis. Modern medicine is now trying to establish circulating biomolecules as the gold standard of biomarkers. Among the molecules that can be released from tumor cells we can find microRNAs. The aim of this study was to evaluate the applicability of cancer-related miR-210, miR-218, miR-221 and miR-1233 as prognostic biomarkers for RCC. Patients with higher levels of miR-210, miR-221 and miR-1233 presented a higher risk of specific death by RCC and a lower cancer-specific survival. The addition of miR-210, miR-221 and miR-1233 plasma levels information improved the capacity to predict death by cancer in 8, 4% when compared to the current variables used by clinicians. We also verified that hypoxia stimulates the release of miR-210 and miR-1233 from HKC-8, RCC-FG2 and 786-O cell lines. These results support the addition of circulating microRNAs as prognostic biomarkers for RCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.